An evaluation of the FDA's analysis of the costs and benefits of the graphic warning label regulation
Chaloupka FJ, Warner KE, Acemoğlu D, Gruber J, Laux F, Max W, Newhouse J, Schelling T, Sindelar J. An evaluation of the FDA's analysis of the costs and benefits of the graphic warning label regulation. Tobacco Control 2014, 24: 112. PMID: 25550419, PMCID: PMC4345832, DOI: 10.1136/tobaccocontrol-2014-052022.Peer-Reviewed Original ResearchMeSH KeywordsCost-Benefit AnalysisDrug LabelingGovernment RegulationHumansPleasureProduct LabelingSmokingTobacco IndustryTobacco ProductsUnited StatesUnited States Food and Drug AdministrationConceptsEconomic impact analysisSound economic analysisNet economic benefitsImpact analysisProminent economistsSignificant regulatory actionsEconomic analysisDrug Administration's regulatory authorityNet benefitEconomic benefitsTobacco productsGraphic warning labelsRegulatory authoritiesLabel regulationsCostTobacco product regulationRegulatory actionProduct regulationEconomistsAuthoritiesBenefitsFuture analysesRulesControl ActJurisdictions